Volume 14, Number 1—January 2008
THEME ISSUE
International Polar Year
Research
International Circumpolar Surveillance System for Invasive Pneumococcal Disease, 1999–2005
, Shelley L. Deeks†1, Tammy Zulz*, Dana Bruden*, Christine Navarro†, Marguerite Lovgren‡, Louise Jette§, Karl G. Kristinsson¶, Gudrun Sigmundsdottir¶, Knud Brinkløv Jensen#, Oistein Lovoll**, J. Pekka Nuorti††, Elja Herva‡‡, Anders Nystedt§§, Anders Sjostedt¶¶, Anders Koch##, Thomas W. Hennessy*, Alan J. Parkinson*, and the International Circumpolar Surveillance System for Invasive Pneumococcal Disease Working Group
Table 3
Annualized crude and standardized incidence rates (per 100,000 persons) of IPD by countries not using 7-valent pneumococcal conjugate vaccine*
| Statistic or age group | Greenland (2000–2005) | Iceland (2000–2005) | Norway (2000–2005) | Northern Sweden (2003–2005) | Finland (2000–2005) |
|---|---|---|---|---|---|
| Total no. cases | 69 | 274 | 5,744 | 88 | 4,049 |
| Age-specific annualized incidence rates (no. cases) | |||||
| <2 y | 77.4 (8) | 89.8 (45) | 50.0 (355) | 21.1 (3) | 52.3 (367) |
| 2–19 y | 4.8 (5) | 6.8 (32) | 4.9 (312) | 0.0 (0) | 5.0 (346) |
| 20–64 y | 25.5 (53) | 8.9 (90) | 14.5 (2,352) | 9.3 (41) | 10.9 (2,057) |
| >65 y | 16.6 (3) | 53.1 (107) | 66.7 (2,725) | 30.9 (44) | 26.6 (1,279) |
| Crude annualized incidence (all ages) | 20.3 | 15.9 | 21.0 | 11.6 | 12.9 |
| Annualized age standardized incidence† | 19.8 | 14.6 | 16.2 | 9.1 | 11.6 |
*IPD, invasive pneumococcal disease,
†Rates adjusted to 2000 World Health Organization world standard population estimates.
1Current affiliation: National Centre for Immunisation, Research and Surveillance, Westmead, New South Wales, Australia
2The International Circumpolar Surveillance System for Invasive Pneumococcal Disease Working Group: Jean-François Proulx (Department of Public Health, Nunavik Regional Board of Health and Social Services, Quebec City, Quebec, Canada); Robert Carlin (Department of Public Health, Cree Board of Health and Social Services of James Bay, Montreal, Quebec, Canada); Andre Corriveau, Cheryl Case (Northwest Territory Department of Health and Social Services, Yellowknife, Northwest Territories, Canada); Bryce Larke, Colleen Hemsley (Yukon Health and Social Services, Whitehorse, Yukon, Canada); Isaac Sobel, Carolina Palacios (Nunavut Department of Health, Iqaluit, Nunavut, Canada); Gregory Tyrell, Marguerite Lovgren (National Centre for Streptococcus, Edmonton, Alberta, Canada); Alisa Reasonover, Michael G. Bruce, Tammy Zulz, Dana Bruden, Thomas W. Hennessy, Alan J. Parkinson (Centers for Disease Control and Prevention, Anchorage, Alaska, USA); Shelley L. Deeks (National Centre for Immunisation, Research and Surveillance, Westmead, New South Wales, Australia); Christine Navarro (Public Health Agency of Canada, Ottawa, Ontario, Canada); Louise Jette (Quebec Public Health Laboratory, Ste. Anne-de-Bellevue, Quebec, Canada); Karl Kristinsson, Gudrun Sigmundsdottir (Landspitali University Hospital, Reykjavik, Iceland); Knud Brinkløv Jensen (Institution of the Chief Medical Officer, Nuuk, Greenland); Oistein Lovoll (Norwegian Institute of Public Health, Oslo, Norway); J. Pekka Nuorti (National Public Health Institute, Helsinki, Finland); Elja Herva (National Public Health Institute, Oulu, Finland); Anders Sjostedt (Umea University, Umea, Sweden); Anders Nystedt (Sunderby Hospital, Lulea, Sweden); and Anders Koch (Statens Serum Institut, Copenhagen, Denmark)